Categories: Health

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Xenon Pharmaceuticals Inc.

VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,200 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 31, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price of $30.54 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of July 31, 2025. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s 2025 Inducement Equity Incentive Plan.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com

For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com

GlobeNews Wire

Recent Posts

EDS Service Solutions to Showcase Comprehensive Staffing and Workforce Solutions at The Hospitality Show 2025

ATLANTA--(BUSINESS WIRE)--#CarRentalIndustry--EDS Service Solutions (EDS) announced it will exhibit at The Hospitality Show 2025, Oct.…

6 minutes ago

Teasdale Latin Foods Issues Allergy Alert on Potential Undeclared Milk in Certain Taco Dinner Kits

CARROLLTON, Texas--(BUSINESS WIRE)--Teasdale Foods, Inc. is recalling certain Taco Dinner Kits, because they may contain…

6 minutes ago

UAE Breaks Ground on World’s First Gigascale Round-the-Clock Renewable Energy Project, Setting a New Global Standard For Clean Energy

In line with the vision of His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of…

8 minutes ago

WSPN Launches Checkout: Bringing Stablecoin Payment Infrastructure to E-Commerce

TORTOLA, British Virgin Islands, Oct. 24, 2025 /PRNewswire/ -- Worldwide Stablecoin Payment Network (WSPN), a leading…

8 minutes ago

Bybit Enhances Capital Mobility for VIP and Institutional Traders with Expanded Withdrawal Limits

DUBAI, UAE, Oct. 24, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume,…

4 hours ago

Bybit TradFi Launches Referral Program Offering Up to 30% in Rewards

DUBAI, UAE, Oct. 24, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading…

4 hours ago